Clinical trials: Camrelizumab
Non-Small-Cell Lung Cancer
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
This study is a randomized, double-blind, placebo-controlled, multi-center clinical study. Target population is patients with stage IV non-small cell lung cancer who had not received systemic chemotherapy.
- Trial name
- NCT04768075
- Testing
- Camrelizumab, Cisplatin, Carboplatin
- Where
- 14 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangdong Association of Clinical Trials
Metastatic Colorectal Cancer
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
The incidence and mortality of colorectal cancer in China's cancer disease spectrum is on the rise, and it is a common malignant tumor that harms the health of Chinese residents.This study was a one-arm, single-center, open…
- Trial name
- NCT03912857
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Small-cell Lung Cancer
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
This single-arm, Phase II, multicenter study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) in combination with Apatinib+carboplatin plus (+) etoposide in…
- Trial name
- NCT04683198
- Testing
- camrelizumab, Apatinib Mesylate, Carboplatin
- Volunteers
- 69 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Rectal Cancer
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for…
- Trial name
- NCT07527026
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese PLA General Hospital
Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with different tumor burden advanced-stage…
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06632106
- Testing
- hepatic artery infusion chemotherapy, Tyrosine kinase inhibitor (TKIs), Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Hospital of China Medical University
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
This randomized, multicenter,open-label, phase II study is to evaluate the effects of PD-1 inhibitor combination with autologous cytokine-induced killer cell immunotherapy in the second-line treatment of patients with metastatic…
- Trial name
- NCT03987698
- Testing
- SHR-1210, CIK cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumor
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.
- Trial name
- NCT03871855
- Testing
- SHR-1702, Camrelizumab
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative
- Trial name
- NCT05613478
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 130 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ovarian Clear Cell Carcinoma
A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma
This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma.
- Trial name
- NCT05600998
- Testing
- Camrelizumab
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Salivary Gland Carcinoma, Precision Therapy
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and…
- Trial name
- NCT06145308
- Testing
- Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College
Colorectal Cancer
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed second-line and above treatment.
- Trial name
- NCT04298320
- Testing
- SHR-1210, AIN 457
- Volunteers
- 40 people
- Sponsor
- Yanqiao Zhang
Breast Neoplasms
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
The purpose of this clinical trial is to understand the safety and tolerability of CircFAM53B-219aa DC vaccine monotherapy and its combination with camrelizumab in the treatment of HER2-negative advanced breast cancer, as well as…
- Trial name
- NCT06530082
- Testing
- CircFam53B-219aa DC vaccine, camrelizumab
- Volunteers
- 48 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer, Second-line Therapy
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2)…
- Trial name
- NCT07320586
- Testing
- Camrelizumab, Nab paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Tumor Hospital
Hepatocellular Carcinoma
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma.
- Trial name
- HZ-T-PD1-APA (NCT03793725)
- Testing
- SHR1210, Apatinib
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
- Trial name
- NCT04701060
- Testing
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Carcinoma
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
To evaluate the efficacy and safety of neoadjuvant therapy of camrelizumab combined with chemotherapy for resectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05476380
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Hepatocellular Carcinoma
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (DST) to guide…
- Trial name
- NCT07351513
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 94 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital